Evidence for the heterologous benefits of prior bcg vaccination on covishield™ vaccine-induced immune responses in sars-cov-2 seronegative young indian adults

HIGHLIGHTS

• who: Srabanti Rakshit from the Children`s Hospital, Australia Cornell University, United States have published the research work: Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELDu2122 vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults, in the Journal: (JOURNAL)
• what: A prospective observational study was conducted to evaluate the effect of BCG revaccination on subsequent anti-SARS-CoV-2 vaccination. The authors demonstrate BCG-specific CD4+ T-cell responses to persist until T6 i.e. 78-94 weeks post BCG revaccination , with no change in Mtb-specific CD8 T . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.